Exendin-4 (Exenatide)
Also known as: Byetta, Bydureon, Exenatide, Exendin-4
Overview
Exendin-4 is a 39-amino acid peptide originally isolated from the venom of the Gila monster lizard (Heloderma suspectum) that shares 53% sequence homology with human GLP-1 but has a much longer half-life of 2.4 hours due to resistance to DPP-4 cleavage at its N-terminus. The synthetic form, exenatide (Byetta/Bydureon), was the first GLP-1 receptor agonist approved by the FDA (2005) for type 2 diabetes management. It demonstrated that pharmacological GLP-1 receptor agonism was a viable therapeutic approach, paving the way for the GLP-1 agonist class that now includes semaglutide and tirzepatide.
Mechanism of Action
Exenatide binds and activates the GLP-1 receptor (GLP-1R), a class B GPCR expressed in pancreatic beta cells, hypothalamic neurons, GI tract, cardiac muscle, and kidneys. GLP-1R activation drives Gs-mediated cAMP production and PKA activation in beta cells, enhancing glucose-dependent insulin secretion while simultaneously suppressing glucagon. Central GLP-1R activation in hypothalamic arcuate and nucleus tractus solitarius neurons promotes satiety and reduces food intake. Gastric emptying is delayed, reducing postprandial glucose excursions. The 39 AA sequence with His1-Gly2 at the N-terminus (vs. His1-Ala2 in GLP-1) confers DPP-4 resistance.
Potential Benefits
- Glucose-dependent insulin secretion (only active when blood glucose is elevated)
- Glucagon suppression reducing hepatic glucose output
- Weight loss (3-5 kg average in clinical trials)
- Cardiovascular risk reduction
- First GLP-1 agonist: established the therapeutic class
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 5 mcg SC 2x daily within 60 min before AM and PM meals |
| Intermediate | 10 mcg SC 2x daily (after 1 month titration) |
| Advanced | 2 mg SC once weekly (Bydureon BCise extended-release) |
| Cycle Duration | Chronic for T2D |
FDA-approved (Byetta 2005, Bydureon 2012). GLP-1 analog derived from Gila monster saliva.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection (pen) ~65-75%
Inject abdomen, thigh, or upper arm. Immediate-release: 60 min before meal. Extended-release (Bydureon BCise): anytime.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Exendin-4 (Exenatide):
T2D Combination Therapy
Standard T2D escalation — exenatide + metformin ± basal insulin.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate 2-8°C. After first use, room temperature up to 30 days (Byetta) or single-use (Bydureon). |
|---|
Bydureon BCise requires 15-second vigorous mixing before injection.
Need exact syringe measurements?
Amino Acid Sequence
His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Side Effects & Safety
- Nausea and vomiting (class effect; most common on initiation)
- Diarrhea
- Rare: pancreatitis (class warning)
- Injection site reactions
- Rare: thyroid C-cell tumors (rodent carcinogenicity data, class warning)
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Personal or Family History of Medullary Thyroid Carcinoma or MEN 2
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- Oral Medications (general):
FDA Safety Information
FDA warnings include risk of acute pancreatitis and renal impairment; extended-release form carries a boxed warning for thyroid C-cell tumors.
Pharmacokinetics
| Half-Life | ~2.4 hours (immediate-release); extended-release provides sustained exposure |
|---|---|
| Storage | Refrigerate 2-8°C before first use. After first use: up to 30 days at room temperature (<25°C). Do not freeze. |
Synergistic Compounds
The following compounds have been studied alongside Exendin-4 (Exenatide) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.